Plain-English translation of NCT07062627 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new treatment called anbalcabtagene autoleucel, which is a type of cell therapy that uses your own immune cells to fight lymphoma in the brain or central nervous system. Doctors will collect some of your immune cells, reprogram them in a laboratory to recognize and attack lymphoma cells, and then give them back to you as a single infusion. This is the first time this medication is being tested in patients whose lymphoma has spread to or started in the brain.
Brain lymphoma is rare and aggressive, and it tends to come back or stop responding to standard chemotherapy. This medication is designed to work differently than traditional treatments—it teaches your own immune cells to hunt down and destroy lymphoma cells—which may help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
First, you'll have screening visits where doctors confirm you have the right type of lymphoma and check your overall health with blood tests and heart imaging. If you qualify, you'll undergo a procedure called leukapheresis, where a machine collects immune cells from your blood (similar to blood donation). Your cells are then sent to a laboratory to be reprogrammed over several weeks. Once ready, you'll return to the clinic for a single infusion of the treated cells, which happens in about 30 minutes. After that, you'll have multiple follow-up visits to monitor how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
South Korea